Matches in Wikidata for { <http://www.wikidata.org/entity/Q86806662> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q86806662 description "article scientifique publié en 2014" @default.
- Q86806662 description "artículu científicu espublizáu en xineru de 2014" @default.
- Q86806662 description "scientific article published on 24 January 2014" @default.
- Q86806662 description "wetenschappelijk artikel" @default.
- Q86806662 description "наукова стаття, опублікована в січні 2014" @default.
- Q86806662 name "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course" @default.
- Q86806662 name "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course" @default.
- Q86806662 type Item @default.
- Q86806662 label "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course" @default.
- Q86806662 label "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course" @default.
- Q86806662 prefLabel "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course" @default.
- Q86806662 prefLabel "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course" @default.
- Q86806662 P1433 Q86806662-1B83207F-2910-4FA5-9E44-9BF83293C826 @default.
- Q86806662 P1476 Q86806662-2E9FE45A-7DCE-4678-828B-EA10A633DF7C @default.
- Q86806662 P2093 Q86806662-16231C20-96BE-4D47-B1F6-E6ACBBFC35AB @default.
- Q86806662 P2093 Q86806662-390DBFF4-38DB-4D46-A603-E54782112785 @default.
- Q86806662 P2093 Q86806662-4A642FC0-9FF8-40F1-A0E9-3D875274A52B @default.
- Q86806662 P2093 Q86806662-583F86F4-DE9D-491C-905F-2317BD3AD45E @default.
- Q86806662 P2093 Q86806662-5C7A085E-6E01-4D36-98C9-E8D618DB6AB2 @default.
- Q86806662 P2093 Q86806662-7AC13EB5-FE19-4C57-BB82-EAC8747FC406 @default.
- Q86806662 P2093 Q86806662-8741BCD1-BCDE-4C7B-9FF5-1B8EBE664246 @default.
- Q86806662 P2093 Q86806662-903A99C5-19F0-4664-8369-EBFA4F53B6EC @default.
- Q86806662 P2093 Q86806662-99BAA469-9DEC-4384-9073-652C67379C38 @default.
- Q86806662 P2093 Q86806662-B4FEB882-B2AE-4971-A340-D01075C1AD18 @default.
- Q86806662 P2093 Q86806662-ECFE4E1A-CBD3-415A-BAD6-62234252F89C @default.
- Q86806662 P2093 Q86806662-FC01599F-02D9-4955-8759-C85367502428 @default.
- Q86806662 P304 Q86806662-E9CC66A6-E6D6-47AE-8217-CB67FB02F92A @default.
- Q86806662 P31 Q86806662-EB311933-4A9A-4A3D-8B0C-C623FCDDCB87 @default.
- Q86806662 P356 Q86806662-902F6D91-63DD-446D-989C-1B966E57C645 @default.
- Q86806662 P433 Q86806662-C7B4DEC4-8AF5-45C9-924B-0AA488C0A98C @default.
- Q86806662 P478 Q86806662-1382BE2C-C047-499D-90D0-3DB035E07180 @default.
- Q86806662 P50 Q86806662-0831F62D-3AB0-4843-8389-FCD3B851E592 @default.
- Q86806662 P50 Q86806662-0CB2AE5C-AA78-4B56-B9E1-66AAF3114F2D @default.
- Q86806662 P577 Q86806662-9E8F44B7-513B-4B21-BCD1-C134472A2D47 @default.
- Q86806662 P698 Q86806662-3FC18CD2-2E73-4225-BC31-11E137AF7AC2 @default.
- Q86806662 P921 Q86806662-A8EE3D4C-1195-4977-A8BA-58D788C8C40B @default.
- Q86806662 P356 10428194.2013.867489 @default.
- Q86806662 P698 24255981 @default.
- Q86806662 P1433 Q6534493 @default.
- Q86806662 P1476 "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course" @default.
- Q86806662 P2093 "Athos Gianella-Borradori" @default.
- Q86806662 P2093 "Françoise Huguet-Rigal" @default.
- Q86806662 P2093 "Igor Wolfgang Blau" @default.
- Q86806662 P2093 "Jürgen Krauter" @default.
- Q86806662 P2093 "Malin Johansen" @default.
- Q86806662 P2093 "Norbert Vey" @default.
- Q86806662 P2093 "Richard F Schlenk" @default.
- Q86806662 P2093 "Thomas Kindler" @default.
- Q86806662 P2093 "Tove Flem Jacobsen" @default.
- Q86806662 P2093 "Trygve Bergeland" @default.
- Q86806662 P2093 "Utz Krug" @default.
- Q86806662 P2093 "Xavier Thomas" @default.
- Q86806662 P304 "2114-2119" @default.
- Q86806662 P31 Q13442814 @default.
- Q86806662 P356 "10.3109/10428194.2013.867489" @default.
- Q86806662 P433 "9" @default.
- Q86806662 P478 "55" @default.
- Q86806662 P50 Q56655096 @default.
- Q86806662 P50 Q92624494 @default.
- Q86806662 P577 "2014-01-24T00:00:00Z" @default.
- Q86806662 P698 "24255981" @default.
- Q86806662 P921 Q264118 @default.